CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Carfilzomib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02491359
NCT02491359Phase 2Completed
CompareCT.gov

Carfilzomib for Treatment of Chronic Graft vs. Host Disease

Fred Hutchinson Cancer Center·interventional·Posted Jul 8, 2015·Updated Feb 6, 2019

In Brief

A Phase 2 clinical trial evaluating Carfilzomib, Laboratory Biomarker Analysis, and 2 other interventions for Chronic Graft Versus Host Disease. Completed, enrolled 20 participants across 5 sites.

Detailed Summary

This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually occurring more than three months after transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective treatment for chronic graft-versus-host disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft Versus Host Disease
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 8, 2015
Enrollment StartNov 12, 2015
Primary CompletionFeb 19, 2018
Study CompletionSep 12, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.0 years ago

Interventions

Carfilzomibdrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies